Xyotax Retains Fast Track Status For Certain Female Lung Cancer Patients

Trials of Xyotax in women with lung cancer who have normal estrogen levels are landmark studies using estrogen as a biomarker, CTI says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet